14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AORT vs UFPT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over Artivion, Inc. (AORT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AORT carries a Unified Composite Score of 45.4/100 (HOLD) at $18.47 (35.5x Forward P/E, 7.6% operating margin), whereas UFPT carries 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin).
Composite vs. Pillar Nuance: While AORT currently prints a higher short-term Unified Composite Score (45.4/100 HOLD vs. UFPT 42.6/100 HOLD), UFPT captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (15.4% vs. 7.6% operating margin) and revenue trajectory (+11.6% vs. +9.2% YoY).
Technical & Structure Timing Caution: AORT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.4); meanwhile UFPT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AORT vs UFPT. Trailing 12-month operating profitability (AORT 7.6% vs UFPT 15.4%) and valuation multiples (AORT 35.5x vs UFPT 24.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $2.4B market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment13.5% of Rev ($88M)
90D Engineering Disclosures0 Published
Investor FAQ AORT vs UFPT Key Questions & Quantitative Answers
As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over Artivion, Inc. (AORT) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AORT carries a Unified Composite Score of 45.4/100 (HOLD) at $18.47 (35.5x Forward P/E, 7.6% operating margin), whereas UFPT carries 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin). Composite vs. Pillar Nuance: While AORT currently prints a higher short-term Unified Composite Score (45.4/100 HOLD vs. UFPT 42.6/100 HOLD), UFPT captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (15.4% vs. 7.6% operating margin) and revenue trajectory (+11.6% vs. +9.2% YoY). Technical & Structure Timing Caution: AORT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.4); meanwhile UFPT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
UFPT leads the Growth & Scale pillar: AORT posts +9.2% YoY revenue growth and +0.0% YoY earnings growth on $482M TTM revenue (63.3% gross margin, 7.6% operating margin), compared with UFPT at +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin). On trailing 12-month operating scale, AORT generates $482M in USD-normalized revenue versus $650M for UFPT. In operating R&D and SG&A reinvestment, AORT deploys 55.7% of Rev ($268M) (0 90-day corporate R&D disclosures) versus 13.5% of Rev ($88M) (0 disclosures) for UFPT.
UFPT screens cheaper on headline valuation multiples. AORT trades at 35.5x Forward P/E, 30.2x Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-9.2% FCF margin), whereas UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AORT (-4.0% ROE) versus UFPT (17.2% ROE) capital efficiency.
In options market volatility and institutional positioning, AORT carries 111.7% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.45β · 92% Vol realized risk). By comparison, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.